Plasma gamma-glutamylglycine predicts the seroconversion of hepatitis B e antigen in patients with chronic hepatitis B - Scorecard - MDSpire

Plasma gamma-glutamylglycine predicts the seroconversion of hepatitis B e antigen in patients with chronic hepatitis B

  • By

  • Ze-Hua Zhao

  • Zheng-Jie Qu

  • Xin-Hua Guo

  • Xue-Qi Yang

  • Qi An

  • Fang-Ming Zhou

  • Jing-Hui Tian

  • Yu-Chen Fan

  • June 8, 2026

  • 0 min

Share

Clinical Scorecard: Plasma Levels of Gamma-Glutamylglycine as Predictors of Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B Patients

At a Glance

CategoryDetail
Condition
Key MechanismsAltered amino acid metabolism and plasma levels of gamma-glutamylglycine associated with HBeAg seroconversion, emphasizing the metabolic profiles.
Target Population
Care Setting

Key Highlights

  • additional_context

Guideline-Based Recommendations

Diagnosis

    Management

    • Include specific treatment protocols for PEG-IFNα and nucleos(t)ide analogues.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Discuss the implications of achieving HBeAg seroconversion for long-term patient outcomes.

        Clinical Best Practices

        • examples

        Related Resources & Content

        Original Source(s)

        Plasma gamma-glutamylglycine predicts the seroconversion of hepatitis B e antigen in patients with chronic hepatitis B

        • by Ze-Hua Zhao, Zheng-Jie Qu, Xin-Hua Guo, Xue-Qi Yang, Qi An, Fang-Ming Zhou, Jing-Hui Tian, Yu-Chen Fan

        • June 8, 2026

        Related Content

        Immunological research landscapes and emerging immune mechanisms in HIV/HBV co-infection: a bibliometric analysis (2014–2024)

        The role of mitochondrial dynamics in metabolic dysfunction–associated steatotic liver disease

        Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages